oxybutynin has been researched along with Cardiomyopathy, Hypertrophic in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imori, Y | 1 |
| Takano, H | 1 |
| Mase, H | 1 |
| Matsuda, J | 1 |
| Sangen, H | 1 |
| Izumi, Y | 1 |
| Tokita, Y | 1 |
| Yamamoto, T | 1 |
| Shimizu, W | 1 |
1 other study available for oxybutynin and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Bisoprolol transdermal patch for perioperative care of non-cardiac surgery in patients with hypertrophic obstructive cardiomyopathy.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; | 2019 |